Skip to main content
Top
Published in: Rheumatology International 2/2015

01-02-2015 | Short Communication

Frequent involvement of central nervous system in primary Sjögren syndrome

Authors: Isabel Moreira, Filipa Teixeira, Ana Martins Silva, Carlos Vasconcelos, Fátima Farinha, Ernestina Santos

Published in: Rheumatology International | Issue 2/2015

Login to get access

Abstract

Primary Sjögren syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration of the salivary and tear glands, and autoantibody secretion, in the absence of other systemic autoimmune disorder. Among autoimmune diseases, it is a relatively common disease, but the burden of central nervous system (CNS) involvement is controversial. This retrospective study evaluates the prevalence, clinical patterns and outcomes of CNS involvement in a cohort of patients with primary Sjögren syndrome. We evaluated 93 patients with pSS diagnosed according to American-European Consensus Group criteria. Fourteen patients (15.1 %) had CNS involvement. All were women with an average age of onset of the disease of 42.1 ± 14.7 years (average ± SD) and an average age of onset of neurological involvement of 47.29 ± 16 years. Three had parkinsonian syndrome, two epilepsy, two motor and sensory deficits, two headache with brain magnetic resonance abnormalities, two neuromyelitis optica, two chronic progressive myelitis and one aseptic meningitis. Neurological involvement preceded Sjögren syndrome diagnosis in nine of the patients (64 %), and neurological outcome was good in 11 patients (78.6 %). Central nervous involvement was not as rare as expected, and the frequency was similar to the frequency of peripheral nervous system involvement. In half of the patients, this was the first symptom of the disease, emphasizing the importance of considering this diagnosis, especially in young female with neurological symptoms without other evident cause.
Literature
1.
go back to reference Tzioufas AG, Mitsias DI, Moutsopoulos HM (2008) Sjögren’s syndrome. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology. Elsevier, Philadelphia, pp 1348–1349 Tzioufas AG, Mitsias DI, Moutsopoulos HM (2008) Sjögren’s syndrome. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology. Elsevier, Philadelphia, pp 1348–1349
2.
go back to reference Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 9(5):A305–A310PubMedCrossRef Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 9(5):A305–A310PubMedCrossRef
3.
go back to reference Delalande S, de Seze J, Fauchais AL et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83(5):280–291CrossRef Delalande S, de Seze J, Fauchais AL et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83(5):280–291CrossRef
4.
go back to reference Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558PubMedCentralPubMedCrossRef Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558PubMedCentralPubMedCrossRef
5.
go back to reference Teixeira F, Moreira I, Silva A et al (2013) Neurological involvement in primary Sjögren’s syndrome. Acta Reumatol Port 38(1):29–36PubMed Teixeira F, Moreira I, Silva A et al (2013) Neurological involvement in primary Sjögren’s syndrome. Acta Reumatol Port 38(1):29–36PubMed
6.
go back to reference Gono T, Kawaguchi Y, Katsumata Y et al (2011) Clinical manifestations of neurological involvement in primary Sjogren’s syndrome. Clin Rheumatol 30(4):485–490PubMedCrossRef Gono T, Kawaguchi Y, Katsumata Y et al (2011) Clinical manifestations of neurological involvement in primary Sjogren’s syndrome. Clin Rheumatol 30(4):485–490PubMedCrossRef
7.
go back to reference Massara A, Bonazza S, Castellino G et al (2010) Central nervous system involvement in Sjögren’s syndrome: unusual, but not unremarkable—clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 49(8):1540–1549CrossRef Massara A, Bonazza S, Castellino G et al (2010) Central nervous system involvement in Sjögren’s syndrome: unusual, but not unremarkable—clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 49(8):1540–1549CrossRef
8.
go back to reference Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87(4):210–219CrossRef Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87(4):210–219CrossRef
9.
go back to reference Baldini C, Tavoni A, Merlini G et al (2005) Primary Sjogren’s syndrome: clinical and serological feature of a single centre. Reumatismo 57(4):256–261PubMed Baldini C, Tavoni A, Merlini G et al (2005) Primary Sjogren’s syndrome: clinical and serological feature of a single centre. Reumatismo 57(4):256–261PubMed
10.
go back to reference Muñoz Mda G, Castelão WC, Saraiva FM et al (2004) Primary Sjögren’s syndrome: exocrine and non-exocrine manifestations. Rev Bras Reumatol 44(2):129–138PubMedCrossRef Muñoz Mda G, Castelão WC, Saraiva FM et al (2004) Primary Sjögren’s syndrome: exocrine and non-exocrine manifestations. Rev Bras Reumatol 44(2):129–138PubMedCrossRef
11.
go back to reference García-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjogren Syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 81(4):270–280CrossRef García-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjogren Syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 81(4):270–280CrossRef
12.
go back to reference Dalakas MC (2006) B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 112(1):57–70PubMedCrossRef Dalakas MC (2006) B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 112(1):57–70PubMedCrossRef
13.
14.
go back to reference Walker RH, Spiera H, Brin MF et al (1999) Parkinsonism associated with Sjögren’s syndrome: three cases and a review of the literature. Mov Disord 14(2):262–268PubMedCrossRef Walker RH, Spiera H, Brin MF et al (1999) Parkinsonism associated with Sjögren’s syndrome: three cases and a review of the literature. Mov Disord 14(2):262–268PubMedCrossRef
15.
go back to reference Ishida K, Uchihara T, Mizusawa H (2007) Recurrent aseptic meningitis: a new CSF complication of Sjogren’s syndrome. J Neurol 254(6):806–807PubMedCrossRef Ishida K, Uchihara T, Mizusawa H (2007) Recurrent aseptic meningitis: a new CSF complication of Sjogren’s syndrome. J Neurol 254(6):806–807PubMedCrossRef
Metadata
Title
Frequent involvement of central nervous system in primary Sjögren syndrome
Authors
Isabel Moreira
Filipa Teixeira
Ana Martins Silva
Carlos Vasconcelos
Fátima Farinha
Ernestina Santos
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3097-9

Other articles of this Issue 2/2015

Rheumatology International 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine